keyword
https://read.qxmd.com/read/38036004/a-self-assembled-graphene-oxide-adjuvant-induces-both-enhanced-humoral-and-cellular-immune-responses-in-influenza-vaccine
#21
JOURNAL ARTICLE
Shiyi Huang, Yiyang Li, Shuang Zhang, Youming Chen, Wenqiong Su, David J Sanchez, John D H Mai, Xiao Zhi, Hongjun Chen, Xianting Ding
Antiviral vaccine is essential for preventing and controlling virus spreading, along with declining morbidity and mortality. A major challenge in effective vaccination lies in the ability to enhance both the humoral and cellular immune responses by adjuvants. Herein, self-assembled nanoparticles based on graphene oxide quantum dots with components of carnosine, resiquimod and Zn2+ ions, namely ZnGC-R, are designed as a new adjuvant for influenza vaccine. With its high capability for antigen-loading, ZnGC-R enhances antigen utilization, improves DC recruitment, and activates antigen-presenting cells...
November 28, 2023: Journal of Controlled Release
https://read.qxmd.com/read/37939778/an-innovative-nanoformulation-utilizing-tumor-microenvironment-responsive-peg-polyglutamic-coating-and-dynamic-charge-adjustment-for-specific-targeting-of-er-stress-inducer-microrna-and-immunoadjuvant-in-pancreatic-cancer-in-vitro-investigations
#22
JOURNAL ARTICLE
Ching-Yao Li, Tsui-Fen Chou, Yu-Li Lo
Pancreatic ductal adenocarcinoma (PDAC) is a significant obstacle to lowering global cancer deaths. CB-5083, a novel valosin-containing protein (VCP)/p97 inhibitor that disrupts proteasomal degradation and induces endoplasmic reticulum stress (ERS) accumulation, was evaluated as an inducer of immunogenic cell death (ICD) in PDAC treatment. Furthermore, miR-142 enhances checkpoint blockade and promotes M1 repolarization, while Toll-like receptor 7/8 agonist resiquimod (R) acts as an immunoadjuvant to amplify the immune response to miR-142...
November 6, 2023: International Journal of Biological Macromolecules
https://read.qxmd.com/read/37908671/sono-immunotherapy-mediated-controllable-composite-nano-fluorescent-probes-reprogram-the-immune-microenvironment-of-hepatocellular-carcinoma
#23
JOURNAL ARTICLE
Yichi Chen, Bolin Wu, Haitao Shang, Yucao Sun, Huimin Tian, Huajing Yang, Chunyue Wang, Xiaodong Wang, Wen Cheng
BACKGROUND: Despite the clinical efficacy of immunotherapy in treating malignant tumors, its effectiveness is often hampered by the immunosuppressive nature of the tumor microenvironment (TME). In this study, we propose the design of a nanoscale ultrasound contrast agent capable of triggering macrophage polarization and immunogenic cell death (ICD) for the treatment of hepatocellular carcinoma (HCC) through sonodynamic treatment (SDT) and immunotherapy. METHODS: The re-educator (designated as ICG@C3F8-R848 NBs) is composed of the Toll-like receptor agonist resiquimod (R848) and the sonosensitizer Indocyanine green (ICG), utilizing nanobubbles (NBs) as carriers...
2023: International Journal of Nanomedicine
https://read.qxmd.com/read/37875399/enhanced-chemo-immunotherapy-strategy-utilizing-injectable-thermosensitive-hydrogel-for-the-treatment-of-diffuse-peritoneal-metastasis-in-advanced-colorectal-cancer
#24
JOURNAL ARTICLE
Meng Wang, DanRong Hu, Yun Yang, Kun Shi, JiaNan Li, QingYa Liu, YiCong Li, Ran Li, Meng Pan, Dong Mo, Wen Chen, XiCheng Li, ZhiYong Qian
Patients with colorectal cancer (CRC) and diffuse peritoneal metastasis (PM) are not eligible for surgical intervention. Thus, palliative treatment remains the standard of care in clinical practice. Systemic chemotherapy fails to cause drug accumulation at the lesion sites, while intraperitoneal chemotherapy (IPC) is limited by high clearance rates and associated complications. Given the poor prognosis, a customized OxP/R848@PLEL hydrogel delivery system has been devised to improve the clinical benefit of advanced CRC with diffuse PM...
October 24, 2023: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
https://read.qxmd.com/read/37873223/the-human-microglia-responsome-a-resource-to-better-understand-microglia-states-in-health-and-disease
#25
Gijsje J L J Snijders, Katia de Paiva Lopes, Marjolein A M Sneeboer, Benjamin Z Muller, Frederieke A J Gigase, Ricardo A Vialle, Roy Missall, Raphael Kubler, Towfique Raj, Jack Humphrey, Lot D de Witte
UNLABELLED: Microglia, the immune cells of the brain, are increasingly implicated in neurodegenerative disorders through genetic studies. However, how genetic risk factors for these diseases are related to microglial gene expression, microglial function, and ultimately disease, is still largely unknown. Microglia change rapidly in response to alterations in their cellular environment, which is regulated through changes in transcriptional programs, which are as yet poorly understood. Here, we compared the effects of a set of inflammatory and restorative stimuli (lipopolysaccharide, interferon-gamma, resiquimod, tumor necrosis factor-alpha, adenosine triphosphate, dexamethasone, and interleukin-4) on human microglial cells from 67 different donors (N = 398 samples) at the gene and transcript level...
October 13, 2023: bioRxiv
https://read.qxmd.com/read/37831945/reactive-oxygen-species-sensitive-biodegradable-mesoporous-silica-nanoparticles-harboring-theravac-elicit-tumor-specific-immunity-for-colon-tumor-treatment
#26
JOURNAL ARTICLE
Yue Huang, Saifun Nahar, Md Masud Alam, Shuo Hu, Daniel W McVicar, De Yang
Immunotherapy has revolutionized the field of cancer treatment through invigorating robust antitumor immune response. Here, we report the development of a thera peutic vac cine [consisting of high mobility group nucleosome-binding protein 1 (HMGN1), resiquimod/R848, and anti-PD-L1 (αPD-L1)]-loaded reactive oxygen species (ROS)-responsive m esoporous s ilica n anoparticle ( MSN@TheraVac ) for curative therapy of colon cancer. In MSN@TheraVac, αPD-L1 conjugated onto the surface of MSNs via a diselenide bond, which can be rapidly released under the oxidative condition of the tumor microenvironment to avert immunosuppression and effector T cell exhaustion while coloaded HMGN1 and R848 would cooperatively trigger robust tumor-infiltrating dendritic cell (TiDC) maturation and elicitation of antitumor immune responses...
October 13, 2023: ACS Nano
https://read.qxmd.com/read/37824829/multifunctional-photothermal-hydrogel-in-the-second-near-infrared-window-for-localized-tumor-therapy
#27
JOURNAL ARTICLE
Sha Lu, Yingjiao Wu, Yandi Liu, Xiaoyi Sun, Jianghua Li, Juan Li
A copper selenide-embedded gellan gum hydrogel (Cu2- x Se@GG) is designed as an "all-in-one" antitumor agent. The obtained nanocomposite hydrogel exhibits strong near-infrared light absorption and high photothermal conversion efficiency in both the NIR-I and NIR-II biowindows. The photothermal conversion efficiency achieves 58.8% under the irradiation of 0.75 W/cm2 with a 1064 nm laser. Furthermore, the nanocomposite hydrogel has catalase- and peroxidase-mimicking activities, which could alter the tumor microenvironment by reducing hypoxia and/or increasing the production of reactive oxygen species...
October 12, 2023: ACS Applied Bio Materials
https://read.qxmd.com/read/37800478/%C3%AE-ketoglutarate-dependent-kdm6-histone-demethylases-regulate-interferon-stimulated-gene-expression-in-lupus
#28
JOURNAL ARTICLE
Erica N Montano, Moumita Bose, Lihong Huo, Gantsetseg Tumurkhuu, Gabriela De Los Santos, Brianna Simental, Aleksandr B Stotland, Janet Wei, C Noel Bairey Merz, Jo Suda, Gislaine Martins, Sarfaraz Lalani, Kate Lawrenson, Yizhou Wang, Sarah Parker, Swamy Venuturupalli, Mariko Ishimori, Daniel J Wallace, Caroline A Jefferies
OBJECTIVE: Investigate the hypothesis that interferon (IFN) stimulated gene (ISG) expression in systemic lupus erythematosus (SLE) monocytes is linked to changes in metabolic reprogramming and epigenetic regulation of ISG expression. METHODS: Monocytes from healthy volunteers and SLE patients at baseline or following IFNα treatment were analyzed by extracellular flux analysis, proteomics, metabolomics, chromatin immunoprecipitation and gene expression. The histone demethylases KDM6A/B were inhibited using GSK-J4...
October 6, 2023: Arthritis & Rheumatology
https://read.qxmd.com/read/37790490/dendritic-cell-vaccination-in-conjunction-with-a-tlr-agonist-polarizes-interferon-immune-responses-in-malignant-glioma-patients
#29
Robert Prins, Richard Everson, Willy Hugo, Lu Sun, Joseph Antonios, Alexander Lee, Lizhong Ding, Melissa Bu, Sara Khattab, Carolina Chavez, Emma Billingslea-Yoon, Andres Salazar, Benjamin Ellingson, Timothy Cloughesy, Linda Liau
Autologous tumor lysate-pulsed dendritic cell (ATL-DC) vaccination is a promising immunotherapy for patients with high grade gliomas, but responses have not been demonstrated in all patients. To determine the most effective combination of autologous tumor lysate-pulsed DC vaccination, with or without the adjuvant toll-like receptor (TLR) agonists poly-ICLC or resiquimod, we conducted a Phase 2 clinical trial in 23 patients with newly diagnosed or recurrent WHO Grade III-IV malignant gliomas. We then performed deep, high-dimensional immune profiling of these patients to better understand how TLR agonists may influence the systemic immune responses induced by ATL-DC vaccination...
September 12, 2023: Research Square
https://read.qxmd.com/read/37786827/-in-vitro-modulation-of-mtor-hif-1%C3%AE-axis-by-tlr7-8-agonist-resiquimod-in-b-chronic-lymphocytic-leukemia
#30
JOURNAL ARTICLE
Rana M Hanafy, Soheir R Demian, Lobna A Abou-Shamaa, O Ghallab, Eman M Osman
UNLABELLED: Targeting toll-like receptors (TLRs), via TLR agonists, has been implicated in the regulation of immunometabolism. B-chronic lymphocytic leukemia (B-CLL) represents a suitable model for B-cell derived malignancies with shifted metabolic adaptations. Several signaling pathways have been found to be critical in metabolic reprogramming of CLL, including mechanistic target of rapamycin- hypoxia inducible factor-1α (mTOR- HIF-1α) pathway, the main metabolic regulator of glycolysis...
October 2023: Indian Journal of Hematology & Blood Transfusion
https://read.qxmd.com/read/37776767/nanoscale-coordination-polymer-synergizes-photodynamic-therapy-and-toll-like-receptor-activation-for-enhanced-antigen-presentation-and-antitumor-immunity
#31
JOURNAL ARTICLE
Xiaomin Jiang, Jing Liu, Morten J Lee, Cheng Peng, Taokun Luo, Langston Tillman, Ralph R Weichselbaum, Wenbin Lin
While activating antitumor immunity with toll-like receptor (TLR) agonists provides a promising approach toward cancer immunotherapy, existing TLR agonists, including resiquimod (R848), have shown poor tumor selectivity and ineffective TLR activation in tumors for optimal antitumor effects. We hypothesized that improved delivery of TLR agonists to tumors and their effective combination with tumor antigens could significantly enhance their antitumor efficacy. Here, we report a novel nanoscale coordination polymer, Ce6/R848, for the co-delivery of Ce6 photosensitizer to elicit immunogenic cell death via photodynamic therapy (PDT) and cholesterol-conjugated R848 (Chol-R848) for tumor-selective TLR7/8 activation...
September 22, 2023: Biomaterials
https://read.qxmd.com/read/37766179/prolonged-liposomal-delivery-of-tlr7-8-agonist-for-enhanced-cancer-vaccine
#32
JOURNAL ARTICLE
Sehui Kim, Yeji Park, Jeonghun Kim, Sohyun Kim, Kyungmin Choi, Taegyun Kang, Inho Lee, Yong Taik Lim, Soong Ho Um, Chul Kim
Despite numerous studies on cancer treatment, cancer remains a challenging disease to cure, even after decades of research. In recent years, the cancer vaccine has emerged as a promising approach for cancer treatment, offering few unexpected side effects compared to existing therapies. However, the cancer vaccine faces obstacles to commercialization due to its low efficacy. Particularly, the Toll-like receptor (TLR) adjuvant system, specifically the TLR 7/8 agonist, has shown potential for activating Th1 immunity, which stimulates both innate and adaptive immune responses through T cells...
September 19, 2023: Vaccines
https://read.qxmd.com/read/37751826/drug-drug-conjugates-self-assembled-nanomedicines-triggered-photo-immuno-therapy-for-synergistic-cancer-treatments
#33
JOURNAL ARTICLE
Haijing Qu, Longmeng Li, Han Chen, Menghuan Tang, Wei Cheng, Tzu-Yin Lin, Lingyan Li, Bin Li, Xiangdong Xue
Although immunotherapies have made progress in cancer treatment, their clinical response rates vary widely and are typically low due to sparse immune cell infiltration (immune "cold") and suppressive tumor immune microenvironment (TIME). A simple yet effective approach that integrates a variety of immune-stimulating and TIME-modulating functions could potentially address this clinical challenge. Herein, we conjugate two small molecules, including a photosensitizer (pyropheophorbide-a, PA) and a Toll-like receptor 7/8 agonist (resiquimod, R848), into prodrug (PA-R848) that self-assembles into PA-R848 esterase responsive nanoparticles (PARE NPs) with 100% drug composition and synergistic photo-/immune- therapeutic effects...
September 24, 2023: Journal of Controlled Release
https://read.qxmd.com/read/37704614/cell-microparticles-loaded-with-tumor-antigen-and-resiquimod-reprogram-tumor-associated-macrophages-and-promote-stem-like-cd8-t-cells-to-boost-anti-pd-1-therapy
#34
JOURNAL ARTICLE
Xiaoqiong Zhang, Zhaohan Wei, Tuying Yong, Shiyu Li, Nana Bie, Jianye Li, Xin Li, Haojie Liu, Hang Xu, Yuchen Yan, Bixiang Zhang, Xiaoping Chen, Xiangliang Yang, Lu Gan
The durable response rate to immune checkpoint blockade such as anti-programmed cell death-1 (PD-1) antibody remains relatively low in hepatocellular carcinoma (HCC), mainly depending on an immunosuppressive microenvironment with limited number of CD8+ T cells, especially stem-like CD8+ T cells, in tumor tissues. Here we develop engineered microparticles (MPs) derived from alpha-fetoprotein (AFP)-overexpressing macrophages to load resiquimod (R848@M2pep-MPsAFP ) for enhanced anti-PD-1 therapy in HCC. R848@M2pep-MPsAFP target and reprogram immunosuppressive M2-like tumor-associated macrophages (TAMs) into M1-like phenotype...
September 13, 2023: Nature Communications
https://read.qxmd.com/read/37689125/-phytochemical-derived-tumor-associated-macrophage-remodeling-strategy-using-phoenix-dactylifera-l-boosted-photodynamic-therapy-in-melanoma-via-h19-inos-pd-l1-axis
#35
JOURNAL ARTICLE
Aya H Soliman, Rana A Youness, Aya A Sebak, Heba Handoussa
BACKGROUND: The tumor microenvironment (TME) represents a barrier to PDT efficacy among melanoma patients. The aim of this study is to employ a novel muti-tactic TME-remodeling strategy via repolarization of tumor-associated macrophages (TAMs), the main TME immune cells in melanoma, from the pro-tumor M2 into the antitumor M1 phenotype using Phoenix dactylifera L. (date palm) in combination with PDT. METHODS: Screening of different date cultivars was employed to choose extracts of selective toxicity to melanoma and TAMs, not normal macrophages...
September 7, 2023: Photodiagnosis and Photodynamic Therapy
https://read.qxmd.com/read/37516419/in-situ-sprayed-hydrogels-containing-resiquimod-loaded-liposomes-reduce-chronic-osteomyelitis-recurrence-by-intracellular-bacteria-clearance
#36
JOURNAL ARTICLE
Liangjie Tian, Zilin Tan, Yusheng Yang, Shencai Liu, Qingfeng Yang, Yuesheng Tu, Jialan Chen, Hongye Guan, Lei Fan, Bin Yu, Xianhui Chen, Yanjun Hu
At present, surgical debridement and systematic administration of antibiotics represent the mainstay of treatment for chronic osteomyelitis. However, it is now understood that Staphylococcus aureus (S. aureus) can survive within excessively polarized M2 macrophages and evade antibiotics, accounting for the high recurrence of chronic osteomyelitis. Effective treatments for intracellular infection have rarely been reported. Herein, we designed an in situ sprayed liposomes hydrogels spray with macrophage-targeted effects and the ability to reverse polarization and eradicate intracellular bacteria to reduce the recurrence of osteomyelitis...
July 27, 2023: Acta Biomaterialia
https://read.qxmd.com/read/37515076/an-analysis-of-linker-dependent-effects-on-the-apc-activation-and-in-vivo-immunogenicity-of-an-r848-conjugated-influenza-vaccine
#37
JOURNAL ARTICLE
Kali F Crofts, Courtney L Page, Stephanie M Swedik, Beth C Holbrook, Allison K Meyers, Xuewei Zhu, Derek Parsonage, Marlena M Westcott, Martha A Alexander-Miller
Subunit or inactivated vaccines comprise the majority of vaccines used against viral and bacterial pathogens. However, compared to their live/attenuated counterparts, these vaccines often demonstrate reduced immunogenicity, requiring multiple boosters and or adjuvants to elicit protective immune responses. For this reason, studies of adjuvants and the mechanism through which they can improve inactivated vaccine responses are critical for the development of vaccines with increased efficacy. Studies have shown that the direct conjugation of adjuvant to antigen promotes vaccine immunogenicity, with the advantage of both the adjuvant and antigen targeting the same cell...
July 20, 2023: Vaccines
https://read.qxmd.com/read/37477904/carboxymethylated-alginate-resiquimod-micelles-reverse-the-immunosuppressive-tumor-microenvironment-and-synergistically-enhance-the-chemotherapy-and-immunotherapy-for-gastric-cancer
#38
JOURNAL ARTICLE
Jiamin Chen, Xingxing Liu, Shujing Zhao, Hongyican Chen, Tao Lu, Jinfeng Wang, Jiahui Han, Wangran Wu, Xian Shen, Chao Li
Due to the intrinsic weak immunogenicity of tumor cells and the quantitatively and functionally different populations of immune cells, immunosuppression has become the major obstacle for cancer immunotherapy. In this study, the biocompatible alginate was chemically modified with the carboxyethyl linker to facilitate the esterification reaction of the resultant carboxymethylated alginate (CMA) and resiquimod (R848), the agonist of Toll-like receptor 7/8 (TLR7/8a). In aqueous solution, the hydrophilic CMA and the hydrophobic R848 formed stable nanomicelles (CMA-R848) by self-assembling...
July 21, 2023: ACS Applied Materials & Interfaces
https://read.qxmd.com/read/37473808/targeted-co-delivery-of-resiquimod-and-a-sirp%C3%AE-variant-by-liposomes-to-activate-macrophage-immune-responses-for-tumor-immunotherapy
#39
JOURNAL ARTICLE
Dianlong Jia, Yue Lu, Mingjia Lv, Feifei Wang, Xiaomeng Lu, Weifan Zhu, Jianmei Wei, Wen Guo, Renmin Liu, Guangrong Li, Rui Wang, Jun Li, Fengjiao Yuan
Tumor-associated macrophages (TAMs) are the major immune cells infiltrating the tumor microenvironment (TME) and typically exhibit an immunosuppressive M2-like phenotype, which facilitates tumor growth and promotes resistance to immunotherapy. Additionally, tumor cells tend to express high levels of CD47, a "don't eat me" signal, that obstructs macrophage phagocytosis. Consequently, re-educating TAMs in combination with CD47 blockage is promising to trigger intense macrophage immune responses against tumors...
July 18, 2023: Journal of Controlled Release
https://read.qxmd.com/read/37467816/polydopamine-coated-ferric-oxide-nanoparticles-for-r848-delivery-for-photothermal-immunotherapy-in-breast-cancer
#40
JOURNAL ARTICLE
Zeting Yuan, Hai He, Jiafeng Zou, Hongtao Wang, You Chen, Yang Chen, Minbo Lan, Yuzheng Zhao, Feng Gao
Breast cancer, which requires comprehensive multifunctional treatment strategies, is a major threat to the health of women. To develop multifunctional treatment strategies, we combined photothermal therapy (PTT) with immunotherapy in multifunctional nanoparticles for enhancing the anti-tumor efficacy. Fe3 O4 nanoparticles coated with the polydopamine shell modified with polyethylene glycol and cyclic arginine-glycyl-aspartic peptide/anisamide (tNP) for loading the immune adjuvant resiquimod (R848) (R848@tNP) were developed in this research...
July 17, 2023: International Journal of Pharmaceutics
keyword
keyword
69562
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.